EligibleTrials

Clinical trials recruiting for HER2 Mutation-Related Tumors

3
Recruiting trials
24
US states with sites
10
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 3Phase 2 1

Drugs and treatments being studied

InterventionTrials
ALX1481
BBO-102031
Bevacizumab1
FOLFOX1
Fam-Trastuzumab Deruxtecan-Nxki1
Fulvestrant1
IAM13631
Ribociclib1
TTX-MC1381
Trastuzumab1
Tucatinib1
Zanidatamab1

Where trials are recruiting (top US states)

StateRecruiting trials
Florida3
Texas3
California2
Colorado2
Illinois2
Massachusetts2
Missouri2
New York2
Tennessee2
Washington2
Alabama1
Arizona1

Top cities

Houston, Texas 3Aurora, Colorado 2Boston, Massachusetts 2Chicago, Illinois 2Dallas, Texas 2Kansas City, Missouri 2Los Angeles, California 2Nashville, Tennessee 2New York, New York 2Seattle, Washington 2

Self-screener

Recruiting trials

Related conditions

Trials recruiting for HER2 Mutation-Related Tumors often also study these conditions. Each links to its own recruiting-trial list.

Breast cancer 2239Solid Tumor, Adult 38Metastatic breast cancer 131Lung cancer 2180HER2-positive Metastatic Breast Cancer 8HER2-positive breast cancer 75Colorectal cancer 1359Triple-negative breast cancer 138Solid Carcinoma 6Rectal Neoplasms 14

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for HER2 Mutation-Related Tumors trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.